[
  {
    "ts": null,
    "headline": "\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
    "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI® has...",
    "url": "https://finnhub.io/api/news?id=bb211a97e91d4d50dedc6fca65c662e87ce69bd82cfd329b654dd4f232f6d112",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732735925,
      "headline": "\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
      "id": 131674607,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI® has...",
      "url": "https://finnhub.io/api/news?id=bb211a97e91d4d50dedc6fca65c662e87ce69bd82cfd329b654dd4f232f6d112"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea",
    "summary": "TOKYO and CAMBRIDGE, Mass., November 28, 2024 - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI® has been...",
    "url": "https://finnhub.io/api/news?id=f45dcad90a10931b73b4e889a45ad1774b005452e3112d634aa38295d3e33592",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732735492,
      "headline": "Biogen : “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea",
      "id": 131674572,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO and CAMBRIDGE, Mass., November 28, 2024 - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI® has been...",
      "url": "https://finnhub.io/api/news?id=f45dcad90a10931b73b4e889a45ad1774b005452e3112d634aa38295d3e33592"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?",
    "summary": "We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. The Evolving Landscape of Global Healthcare Spending and Innovation The healthcare industry remains a vital and resilient sector which is driven […]",
    "url": "https://finnhub.io/api/news?id=7c964c7e54d9638d21cca04495553a66e2f13162783097cfbfc472b96e54c98d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732716902,
      "headline": "Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?",
      "id": 131676081,
      "image": "https://s.yimg.com/ny/api/res/1.2/xRFTclyUJm6fZwoRk7QefQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. The Evolving Landscape of Global Healthcare Spending and Innovation The healthcare industry remains a vital and resilient sector which is driven […]",
      "url": "https://finnhub.io/api/news?id=7c964c7e54d9638d21cca04495553a66e2f13162783097cfbfc472b96e54c98d"
    }
  }
]